XML 31 R17.htm IDEA: XBRL DOCUMENT v3.19.1
Share-Based Compensation
12 Months Ended
Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation
SHARE-BASED COMPENSATION

Equity Incentive Plans

As of December 31, 2018, there were 1,639,796 options outstanding and no remaining equity awards available for future issuances under the 2008 Plan. All awards granted under the 2008 Plan that, after February 13, 2017, expire or terminate for any reason prior to exercise or settlement, are forfeited, or are reacquired, withheld, or not issued to satisfy a tax withholding obligation or to satisfy the exercise price of a stock award, will become available for grant under the 2016 Plan in accordance with its terms.

The 2016 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and performance awards that may be settled in cash, stock, or other property. All employees and non-employee directors are eligible to participate in the 2016 Plan and may receive all types of awards other than incentive stock options. Incentive stock options may be granted under the 2016 Plan only to employees (including officers) and employees of the Company’s affiliates.

The aggregate number of shares of Common Stock that may be issued under the 2016 Plan will not exceed 4,182,404 shares, which number is the sum of: (i) 1,681,294 shares, plus (ii) the number of shares subject to outstanding stock awards that were granted under the 2008 Plan, that, from and after the closing date of the Merger, expire or terminate for any reason prior to exercise or settlement, are forfeited because of the failure to meet a contingency or condition required to vest such shares, or are reacquired, withheld, or not issued to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award, if any, as such shares become available from time to time, plus (iii) shares from automatic increases to the share reserve, as described in more detail below. In accordance with the 2016 Plan, the share reserve will automatically increase on January 1 of each year, for a period of not more than ten years, commencing on January 1 of the year following the year in which the effective date of the 2016 Plan occurs, and ending on (and including) January 1, 2026, in an amount equal to 4% of the shares of Common Stock outstanding on December 31 of the preceding calendar year; however, the board of directors or compensation committee may act prior to January 1 of a given year to provide that there will be no January 1 increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the automatic increase. On January 1, 2018 and 2019, the share reserve had automatic increases of 902,720 and 1,233,578 shares, respectively. As of December 31, 2018, there were outstanding stock options to purchase 1,887,617 shares of Common Stock and 705,317 shares of Common Stock available for issuance pursuant to the terms under the 2016 Plan.

Options granted under the 2008 Plan and 2016 Plan have an exercise price equal to the market value of the Common Stock at the date of grant and expire ten years from the date of grant. Generally, options vest 25% on the first anniversary of the vesting commencement date and 75% ratably in equal monthly installments over the remaining 36 months. The Company has also granted options that vest in equal monthly or quarterly amounts over periods up to 48 months.

A summary of Common Stock option activity is as follows:
 
Number of Options
(in thousands)
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term
(years)
 
Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 2016
2,321

 
$
1.44

 
 
 
 
Granted
989

 
$
11.37

 
 
 
 
Exercised
(412
)
 
$
0.74

 
 
 
 
Forfeited
(35
)
 
$
11.36

 
 
 
 
Outstanding at December 31, 2017
2,863

 
$
4.85

 
 
 
 
Granted
1,108

 
$
7.37

 
 
 
 
Exercised
(280
)
 
$
0.65

 
 
 
 
Forfeited or canceled
(164
)
 
$
9.52

 
 
 
 
Outstanding at December 31, 2018
3,527

 
$
5.76

 
6.95
 
$
2,698

Vested or expected to vest at December 31, 2018
3,527

 
$
5.76

 
6.95
 
$
2,698

Exercisable as of December 31, 2018
1,979

 
$
4.20

 
5.61
 
$
2,421



The total intrinsic value of stock options exercised during the year ended December 31, 2018 and 2017 was $1.6 million and $3.8 million, respectively. Cash received from the exercise of stock options during the year ended December 31, 2018 and 2017 was approximately $0.2 million and $0.3 million respectively.

Fair Value Assumptions

The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted under its equity compensation plans. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected lives of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on historical data from public companies that are similar to the Company in size and nature of operations. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company accounts for forfeitures as they occur. The risk-free rate for periods within the contractual life of each option is based on the U.S. Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted and expected option-exercise behaviors. Prior to the Merger, Private Miragen estimated the fair value of underlying shares of its common stock using a third-party valuation report that derived the fair value using the probability-weighted expected return method. After the Merger, the fair value of the underlying Common Stock is based on the closing price of the Common Stock on The Nasdaq Capital Market at the date of grant.

Stock Options Granted to Employees and Directors

The weighted-average grant-date fair value of options granted to the Company’s employees and members of its board of directors during the years ended December 31, 2018 and 2017 was $5.41 and $8.27, respectively. The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:
 
Year Ended
December 31,
 
2018
 
2017
Expected term, in years
6.35

 
6.43

Expected volatility
85.2
%
 
83.8
%
Risk-free interest rate
2.6
%
 
2.1
%
Expected dividend yield
%
 
%
Weighted-average exercise price
$
7.37

 
$
11.37



Stock Options Granted to Non-Employees

The Company determines the value of Common Stock options issued to non-employees (other than members of its board of directors) using the Black-Scholes option pricing model and adjusting the value of such awards to current fair value each reporting period until the awards are vested or a performance commitment has otherwise been reached. No Common Stock options were issued to non-employees during the years ended December 31, 2018 and 2017.

Employee Stock Purchase Plan

The 2016 Employee Stock Purchase Plan (“ESPP”) allows qualified employees to purchase shares of the Company’s Common Stock at a price equal to 85% of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. The Company expects that a new 6-month offering period will begin each August 22 and February 22. As of December 31, 2018, the Company had 0.4 million shares available for issuance and 66 thousand shares had been issued under the ESPP.

Share-Based Compensation Expense

Share-based compensation related to all equity awards issued pursuant to the 2008 Plan and 2016 Plan and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the consolidated statements of operations and comprehensive loss as follows:
 
Year Ended
December 31,
 
2018
 
2017
 
(in thousands)
Research and development
$
1,286

 
$
917

General and administrative
2,393

 
1,492

Total share-based compensation expense
$
3,679

 
$
2,409

 
 
 
 
 
 
 
 

As of December 31, 2018, the Company had $8.3 million of total unrecognized employee and non-employee share-based compensation costs, which the Company expects to recognize over a weighted-average remaining period of 2.6 years.